In a report released today, David Saxon from Needham assigned a Hold rating to Irhythm Technologies (IRTC). The company’s shares closed last Thursday at $239.15, close to its 52-week high of $274.21.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of 49.4% and a 100.0% success rate. Saxon covers the Healthcare sector, focusing on stocks such as BioTelemetry, LivaNova, and SI-Bone.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Irhythm Technologies with a $232.83 average price target, implying a 3.1% upside from current levels. In a report issued on December 3, Robert W. Baird also maintained a Hold rating on the stock with a $170.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $274.21 and a one-year low of $56.54. Currently, Irhythm Technologies has an average volume of 380K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
